@monsefderraji Ces données sont en effet préoccupantes pour la MD fam. J’ai beaucoup de respect pour ce que vous faites. Or, pour le poste neurochirurgie, il s’agit d’un contingent particulier, donc je ne pense pas qu’il faut tirer de conclusions de cette donnée https://t.co/kyhOFhobGf
📖 Looking for a good weekend read? Check out the new @ASCO Global Geriatric Oncology Guidelines #gerionc#globonc.
They provide practical, resource-stratified recommendations to improve care for older adults with cancer worldwide. 🌍👵👴
🔗 https://t.co/bQpp9DkGWg
🎧 Listen to the ASCO Guidelines Podcast where we talk about our new Global Geriatric Oncology Guidelines 🌍👵🧓
We discuss why these recommendations matter and how they can improve cancer care for older adults worldwide.
Listen here 👉 https://t.co/oR65wE0ZVF
#gerionc#globonc
In the OASIS-4 phase 3 trial involving women taking endocrine therapy for HR-positive breast cancer, elinzanetant (a neurokinin-targeted therapy) significantly reduced the frequency of moderate-to-severe vasomotor symptoms. Full trial results and Research Summary: https://t.co/yrL8mtlmvd
Thrilled to share our new ASCO Global Guideline on Geriatric Assessment 🌍👵👴 — supporting cancer care for older adults in resource-constrained settings.
Published in @JCOGlobalOncol ➡️ https://t.co/bQpp9DleLO
#gerionc#globonc@ASCO
🆕🧰HOMECARE - for older adults after cancer surgery
🏠Immediate (1 month) & chronic homecare (7–12 months)
📊Strong performance & well-calibrated
For help with risk communication & preop preparatio🤝
Online calculator coming!🧮
https://t.co/bmOKopeQ3C
Presented at #ASCO25:
A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results: https://t.co/j3kWJDjuVz
@ASCO
💥 INTERLACE ticks all the right boxes:
OS ✅ Toxicity ✅ QoL ✅
🧪 Adding induction chemo (IC) before CRT showed an 8% absolute OS benefit at 5 yrs —with a manageable 10% ↑ in grade 3/4 AEs.
But what about QOL? 🤔
No significant QoL drop with IC vs CRT alone, says this substudy https://t.co/gaGqvaeG6M
💪 Survival gain without QoL pain
#GynOnc #GynCSM
Thank you to @gynoncjnls for publishing our invited review article on frailty and optimizing patient-centered care for our older adult patients! https://t.co/lNXDs0iWwy
Vaginal estrogen use in breast cancer survivors: a systematic review and meta-analysis of recurrence and mortality risks - Forest plot for overall mortality https://t.co/ITPmIopd5A